Verici Dx CEO Sara Barrington speaks at Edison Open House: Global Healthcare 2022
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
Tell us about your patient-based focus in the area of kidney transplant.
Which research underpins your platform? • How does this open up treatment options?
What does the US designation of laboratory developed tests (LDT) mean for Clarava and Tuteva, and how does the commercialisation strategy differ in other markets?
Might the technology work for other types of organ transplant?
What are your licensing and intellectual property strategies?
Which milestones should investors focus on in the coming year?